| CTRI Number |
CTRI/2024/10/075620 [Registered on: 22/10/2024] Trial Registered Prospectively |
| Last Modified On: |
21/10/2024 |
| Post Graduate Thesis |
No |
| Type of Trial |
Interventional |
|
Type of Study
|
Drug Surgical/Anesthesia |
| Study Design |
Randomized, Parallel Group Trial |
|
Public Title of Study
|
to compare the time duration of pain relief by adding injection dexmedetomidine and injection butorphanol in erector spinae plane block in children 1 year to 18 years posted for chest and abdominal surgeries |
|
Scientific Title of Study
|
A comparative study of dexmedetomidine and butorphanol as an adjuvant in ultrasound-guided erector spinae plane block for perioperative analgesia in children undergoing thoracoabdominal surgeries |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Shambhavi Sharma |
| Designation |
Senior resident |
| Affiliation |
Postgraduate Institute of Child Health |
| Address |
Department of paediatric anaesthesias
second floor,
postgraduate institute of child health, Sector 30, Noida, Uttar pradesh
Gautam Buddha Nagar UTTAR PRADESH 201301 India |
| Phone |
9606322036 |
| Fax |
|
| Email |
drshambhavi2020@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Dr Mukul Jain |
| Designation |
Professor and head of department |
| Affiliation |
POSTGRADUATE INSTITUTE OF CHILD HEALTH |
| Address |
Department of paediatric anaesthesia,
Second floor,
Postgraduate institute of child health,
Sector 30, Noida, Uttar pradesh
Gautam Buddha Nagar UTTAR PRADESH 201301 India |
| Phone |
9971588623 |
| Fax |
|
| Email |
jainmukul2004@yahoo.com |
|
Details of Contact Person Public Query
|
| Name |
Dr Mukul Jain |
| Designation |
Professor and Head of department |
| Affiliation |
Postgraduate Institute of Child Health |
| Address |
Department of paediatric anaesthesia
second floor,
post graduate institute of child health, Sector 30, Noida, uttar pradesh
Gautam Buddha Nagar UTTAR PRADESH 201301 India |
| Phone |
9971588623 |
| Fax |
|
| Email |
jainmukul2004@yahoo.com |
|
|
Source of Monetary or Material Support
|
|
|
Primary Sponsor
|
| Name |
Post graduate institute of child health |
| Address |
Department of paediatric anaesthesia, second floor,
Post graduate institute of child health,
Sector 75, Noida, uttar pradesh |
| Type of Sponsor |
Research institution and hospital |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Shambhavi Sharma |
Post graduate institute of child health |
Department of paediatric anaesthesia
OT complex, second floor
postgraduate institute of child health, sector 75, noida, Uttar pradesh Gautam Buddha Nagar UTTAR PRADESH |
9606322036
drshambhavi2020@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Institutiona lethics committee |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: Q10-Q18||Congenital malformations of eye, ear, face and neck, (2) ICD-10 Condition: Q20-Q28||Congenital malformations of the circulatory system, (3) ICD-10 Condition: Q60-Q64||Congenital malformations of the urinary system, (4) ICD-10 Condition: Q30-Q34||Congenital malformations of the respiratory system, (5) ICD-10 Condition: Q65-Q79||Congenital malformations and deformations of the musculoskeletal system, (6) ICD-10 Condition: J90-J94||Other diseases of the pleura, (7) ICD-10 Condition: I70-I79||Diseases of arteries, arterioles and capillaries, (8) ICD-10 Condition: N40-N53||Diseases of male genital organs, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Comparator Agent |
Erector spinae plane block with adjuvant injection butorphanol |
In group B - drug will be given 0.125% bupivacaine 0.5ml/kg with adjuvant injection butorphanol 15mcg/kg.
|
| Intervention |
Erector spinae plane block with adjuvant injection dexmedetomidine |
Erector spinae plane block is given ultrasound guided, in group A-drug will be given 0.125% bupivacaine 0.5ml/kg with adjuvant injection dexmedetomidine 0.5 mcg/kg.
|
|
|
Inclusion Criteria
|
| Age From |
1.00 Year(s) |
| Age To |
18.00 Year(s) |
| Gender |
Both |
| Details |
1. Age: 1 year - 18 years
2. ASA I and II patients of either sex
3. Elective thoracic and abdominal surgery.
|
|
| ExclusionCriteria |
| Details |
1. Evidence of coagulopathy or thrombocytopenia
2. History of bleeding or clotting disorders
3. Local infection
4. Allergy to drugs used in study
5. Intellectual disability
6. Chronic pain disorder
7. On chemotherapy
|
|
|
Method of Generating Random Sequence
|
Computer generated randomization |
|
Method of Concealment
|
Sequentially numbered, sealed, opaque envelopes |
|
Blinding/Masking
|
Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded |
|
Primary Outcome
|
| Outcome |
TimePoints |
| duration of analgesia i.e. time of block placement to the time of administration of first rescue analgesia |
upto 24 HOURS |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
1. Pain score at predefined time points following surgery for upto 24 hours
|
POSTOPERATIVELY - ON ARRIVAL,
at 15 minutes, 30 minutes, 60 minutes, 90 minutes and 120 minutes, 4 hourly up to 24 hours |
| haemodynamic stability |
intraoperatively - every 15mins
post operatively - at 15mins, 30 ,60,90,120 minutes, 4hourly upto 24 hours |
|
|
Target Sample Size
|
Total Sample Size="52" Sample Size from India="52"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
Phase 3 |
|
Date of First Enrollment (India)
|
01/11/2024 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="1" Months="0" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Yet Recruiting |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - YES
- What data in particular will be shared?
Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
- What additional supporting information will be shared?
Response - Study Protocol Response - Statistical Analysis Plan Response - Informed Consent Form Response - Clinical Study Report
- Who will be able to view these files?
Response - Researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose.
- For what types of analyses will this data be available?
Response - For individual participant data meta-analysis.
- By what mechanism will data be made available?
Response - Proposals should be directed to [jainmukul2004@yahoo.com].
- For how long will this data be available start date provided 01-08-2026 and end date provided 01-08-2029?
Response - Beginning 9 months and ending 36 months following article publication.
- Any URL or additional information regarding plan/policy for sharing IPD?
Additional Information - nil
|
|
Brief Summary
|
Earlier beliefs held that children
were incapable of feeling pain but now the paediatric pain management has
advanced significantly. It is widely recognised that proper
care in the paediatric intensive care unit (PICU) and pain management are
essential. Pain-related stress in the
paediatric population might affect emotional and neurocognitive outcomes, as
well as cause pain sensitivity in childhood. Regional analgesia is one method of
delivering analgesia without risking narcotic dependence. It has been demonstrated that, the
erector spinae plane block (ESPB) can reduce pain during thoracic and abdominal
procedures. Use of a variety of adjuvant medications
in conjunction with local anaesthetics, including opioids, dexmedetomidine,
clonidine, dexamethasone, and butorphanol, to increase the duration as well as intensity of analgesia.
The present study aims to compare
the effectiveness of dexmedetomidine and butorphanol in reducing post-operative
pain in children having thoraco-abdominal procedures, when used as an adjuvant
with isobaricbupivacaine 0.25%, in erector spinae plane block.
HYPOTHESIS - •Through
this study, I would hypothesize that injection dexmedetomidine is better
adjuvant in ESPB than injection butorphanol as it increases the time of
analgesia of the patient perioperatively. AIMS AND OBJECTIVES - •The aim of this study is to compare
dexmedetomidine and butorphanol as
an adjuvant along with bupivacaine in ultrasound-guided erector spinae plane
block for perioperative analgesia in children undergoing thoracoabdominal
surgeries.
•PRIMARY OUTCOME -
1.Pain score at predefined time
points following surgery for upto 24 hours.
•
•SECONDARY OUTCOME –
1.Timing of rescue analgesia.
2.Haemodynamic stability
AIMS AND OBJECTIVES Following approval by the Departmental Protocol
Committee, Department of Paediatric Anaesthesia, and the Institutional Ethics
Committee, Postgraduate Institute of Child Health (PGICH), Noida, the present
study would be conducted in the institution on paediatric patients
undergoing open thoracic and abdominal surgeries. It is a randomized controlled
study. Informed written consent will be taken from the parents/guardians.
Inclusion Criteria:
1.
Age:
1 year - 18 years
2.
ASA
I and II patients of either sex
3.
Elective
thoracic and abdominal surgery (such as – decortication, chest wall abscess
drainage, herniotomy, exploratory laparotomy etc.)
Exclusion Criteria
1.
Evidence
of coagulopathy or thrombocytopenia
2.
History
of bleeding or clotting disorders
3.
Local
infection
4.
Allergy
to drugs used in study
5. Intellectual
disability
6. Chronic
pain disorder
7. On
chemotherapy
METHODOLOGY All
children would be kept nil per oral before surgery as per standard ASA
guidelines. The intravenous cannula would be secured in the ward before the
patient is shifted to the operating room on the morning of surgery. Premedicate the
child with intravenous midazolam 0.1 mg/kg, glycopyrrolate
4mcg/kg, ketamine 0.5 mg/kg. Transfer to the
operating room, electrocardiography, non-invasive blood pressure, and
pulse oximetry
would be connected. The baseline preoperative parameters recorded. All patients will be randomized to one of
two groups using computer generated random numbers and a 1:1 allocation ratio.
The primary investigator performing the block and the investigator analysing
the data will be blinded to the group allocation. After
induction, patient will be placed in lateral position to apply ESPB. An
assistant, who will be neither involved in the study nor will be participating
in the perioperative period or the postoperative follow-up, will
prepare
study drugs. Group
A will receive injection 0.25% bupivacaine, single shot, 0.5ml/kg with
1 mcg/kg dexmedetomidine and
Group B will receive injection 0.25% bupivacaine, single shot, 0.5ml/kg with 25 mcg/kg butorphanol deep
to the erector spinae
muscle adjacent to transverse processes. After
the block, the patient of either group will be monitored for oxygen saturation,
tachycardia, hypertension and end tidal carbon dioxide every 15 minutes. If
pain persists rescue analgesia in the form of Injection paracetamol
15mg/kg will be administered. The time duration and the time of the block given
till the first dose of rescue analgesia will be noted. On arrival in the post anaesthesia care
unit (PACU), oxygen saturation (SpO2), Heart rate (HR), Mean blood pressure
(MBP), end tidal carbon dioxide (EtCO2) and
age appropriate scoring will be done. FLACC
scoring (<=10 years) and VAS score (>10 years) immediately after the
postoperative period once the patient is awake, then at 15 minutes, at 30
minutes, 60 minutes, 90 minutes and 120 minutes, 4 hourly up to 24 hours. Duration
of analgesia, requirement of rescue analgesia usage and side effects if any
will be noted.
|